Sign In
Buy CATX
$3.56
-0.0400 (-1.11%)
At Close: Jun 03, 2026
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
07:00am, Thursday, 17'th Apr 2025
SEATTLE, April 17, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments
SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for can
Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround
10:35am, Wednesday, 02'nd Apr 2025
Perspective Therapeutics (CATX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ear
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
07:00am, Monday, 31'st Mar 2025
SEATTLE, March 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment a
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results
04:10pm, Wednesday, 26'th Mar 2025
SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical compan
SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment
Perspective Therapeutics to Present at Upcoming March Investor Conferences
07:00am, Wednesday, 26'th Feb 2025
SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results
07:00am, Friday, 21'st Feb 2025
SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering
Perspective Therapeutics to Participate in Upcoming February Investor Conferences
07:00am, Wednesday, 05'th Feb 2025
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment ap
Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer
08:00am, Monday, 06'th Jan 2025
SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tr
Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM
11:13am, Monday, 23'rd Dec 2024
Perspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radia
Perspective Therapeutics: Definitely Not Looking Overvalued Now
04:16pm, Friday, 20'th Dec 2024
Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to con
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December
07:00am, Wednesday, 27'th Nov 2024
SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced tre
